Scintimun 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
IB/0016 
C.I.z - Changes (Safety/Efficacy) of Human and 
12/12/2022 
Veterinary Medicinal Products - Other variation 
amended 
on 
SmPC, 
Labelling and 
PL 
II/0015 
Please refer to the Recommendations section above 
29/09/2022 
n/a 
Not applicable 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
C.I.13 - Other variations not specifically covered 
elsewhere in this Annex which involve the submission 
of studies to the competent authority 
PSUSA/385/2
Periodic Safety Update EU Single assessment - 
05/09/2019 
n/a 
PRAC Recommendation - maintenance 
01901 
besilesomab 
IB/0014 
B.I.b.2.e - Change in test procedure for AS or 
14/05/2019 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IA/0013 
A.4 - Administrative change - Change in the name 
03/04/2019 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
PSUSA/385/2
Periodic Safety Update EU Single assessment - 
01/09/2017 
n/a 
PRAC Recommendation - maintenance 
01701 
besilesomab 
II/0010/G 
This was an application for a group of variations. 
22/09/2016 
06/02/2017 
SmPC 
B.II.b.1.c - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
processes 
Page 2/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.II.b.3.z - Change in the manufacturing process of 
the finished or intermediate product - Other variation 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.b.5.z - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Other variation 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.e.1.a.3 - Change in immediate packaging of the 
finished product - Qualitative and quantitative 
composition - Sterile medicinal products and 
biological/immunological medicinal products 
B.II.e.4.c - Change in shape or dimensions of the 
container or closure (immediate packaging) - Sterile 
medicinal products 
PSUSA/385/2
Periodic Safety Update EU Single assessment - 
02/09/2016 
n/a 
PRAC Recommendation - maintenance 
01601 
besilesomab 
IB/0009 
B.II.f.1.b.5 - Stability of FP - Extension of the shelf 
11/02/2016 
06/02/2017 
SmPC 
life of the finished product - Biological/immunological 
medicinal product in accordance with an approved 
stability protocol 
IB/0007 
C.I.z - Changes (Safety/Efficacy) of Human and 
28/01/2016 
22/02/2016 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II, Labelling 
and PL 
Page 3/4 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/385/2
Periodic Safety Update EU Single assessment - 
09/07/2015 
n/a 
PRAC Recommendation - maintenance 
01501 
besilesomab 
R/0005 
Renewal of the marketing authorisation. 
26/06/2014 
26/08/2014 
SmPC, Annex 
The CHMP, having reviewed the available information on 
II, Labelling 
the status of the fulfilment of post-authorisation measures 
and PL 
and having confirmed the positive benefit/risk balance, is of 
the opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of Scintimun, subject to the Conditions as laid 
down in Annex II to the Opinion. The CHMP recommends 
that the renewal be granted with unlimited validity. 
PSUV/0004 
Periodic Safety Update 
10/07/2014 
n/a 
PRAC Recommendation - maintenance 
IAIN/0003 
B.II.b.1.a - Replacement or addition of a 
16/08/2012 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IG/0015 
C.I.9.e - Changes to an existing pharmacovigilance 
06/08/2010 
n/a 
Annex II 
system as described in the DDPS - Changes in the 
major contractual arrangements with other persons 
or organisations involved in the fulfilment of 
pharmacovigilance obligations and described in the 
DD 
IB/0001 
B.II.d.2.d - Change in test procedure for the finished 
23/07/2010 
n/a 
SmPC 
product - Other changes to a test procedure 
(including replacement or addition) 
Page 4/4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
